ANN ARBOR, Mich., Nov. 15, 2010 /PRNewswire-FirstCall/ —
Adeona Pharmaceuticals, Inc. (Amex:
AEN), a developer of innovative medicines for serious central
nervous system diseases, announced today its third quarter 2010
financial results as well as recent clinical and operational
achievements.

Adeona’s Recent Clinical and Operational
Achievements:

Clinical Programs

Alzheimer’s Disease

• All 60 patients are now enrolled in Part 2 of CooperProof-2
  clinical study evaluating Zinthionein, a new zinc-based treatment
  for Alzheimer’s disease. In this randomized, double-blind,
  placebo-controlled study, patients are assessed 3 and 6 months
  after they begin the once-daily oral treatment or matching placebo.
  These 60 patients should complete their 6 month treatment by the
  end of March 2011 and it is anticipated that top-line clinical
  study results should be available shortly thereafter. If
  successful, Adeona expects to make its Zinthionein product
  commercially available as a prescription medical food for patients
  suffering from Alzheimer’s disease and mild cognitive
  impairment.

• Five peer-reviewed scientific articles have recently been
  published supporting the role of copper toxicity and zinc
  deficiency in Alzheimer’s disease and mild cognitive decline. These
  publications were authored by Adeona’s scientific founder and
  consultant, George J. Brewer, M.D., the Morton S. and Henrietta
  Sellner Emeritus Professor of Human Genetics and Internal Medicine
  at the University of Michigan.

Multiple Sclerosis

• 115 of 150 patients have been enrolled in the clinical trial
  evaluating Trimesta in women suffering from relapsing-remitting
  multiple sclerosis. The randomized, double-blind,
  placebo-controlled cli

  ‘/>”/>

SOURCE